4.6 Article

Personalized thromboprophylaxis using a risk score for the management of pregnancies with high risk of thrombosis: a prospective clinical study

Journal

JOURNAL OF THROMBOSIS AND HAEMOSTASIS
Volume 15, Issue 5, Pages 897-906

Publisher

WILEY
DOI: 10.1111/jth.13660

Keywords

low molecular weight heparin; Lyon VTE score; pregnancy; prophylaxis; venous thromboembolism

Ask authors/readers for more resources

Background: Patients with thrombophilia and/or a history of venous thromboembolism (VTE) are at risk of thrombosis during pregnancy. A risk score for pregnancies with an increased risk of VTE was previously described by our group (Lyon VTE score). Objectives: The aim of this prospective study was to assess the efficacy and safety of our score-based prophylaxis strategy in 542 pregnancies managed between 2005 and 2015 in Lyon University Hospitals. Patients/Methods: Of 445 patients included in the study, 36 had several pregnancies during the study period. Among these 445 patients, 279 had a personal history of VTE (62.7%), 299 patients (67.2%) had a thrombophilia marker, and 131 (29.4%) thrombophilic women had a personal history of VTE. During pregnancy, patients were assigned to one of three prophylaxis strategies according to the risk scoring system. Results: In the antepartum period, low molecular weight heparin (LMWH) prophylaxis was prescribed to 64.5% of patients at high risk of VTE. Among them, 34.4% were treated in the third trimester only, and 30.1% were treated throughout pregnancy. During the postpartum period, all patients received LMWH for at least 6 weeks. Two antepartum-related VTEs (0.37%; one with a score of < 3 and the other with a score of > 6) and four postpartum-related VTEs (0.73%; three with scores of 3-5 and one with a score of > 6) occurred. No case of pulmonary embolism was observed during the study period. The rate of bleeding was 0.37%. No serious bleeding requiring transfusions or surgery occurred during the study period. Conclusion: The use of a risk score may provide a rational decision process to implement safe and effective antepartum thromboprophylaxis in pregnant women at high risk of VTE.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Pharmacology & Pharmacy

Dose tailoring of human cell line-derived recombinant factor VIII simoctocog alfa: Using a limited sampling strategy in patients with severe haemophilia A

Xavier Delavenne, Yesim Dargaud, Edouard Ollier, Claude Negrier

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2019)

Letter Hematology

A single-centre study of management of pregnant women with von Willebrand disease

Zizhen Xu, Yesim Dargaud, Valerie Chamouard, Sandra Le Quellec, Anne Lienhart, Sandrine Meunier, Lucia Rugeri

HAEMOPHILIA (2019)

Article Obstetrics & Gynecology

Pregnancy and thrombosis: Adrenal vein thrombosis. A retrospective descriptive study of 14 cases

Pierre Descargues, Catherine Battie, Cyril Huissoud, Nathalie Hoen, Yesim Dargaud, Muriel Doret, Pascal Gaucherand

EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2019)

Article Hematology

Pregnancy-related thrombosis risk in patients with protein C deficiency and comparison with pregnant women with heterozygous factor V Leiden mutation

Lucia Rugeri, Stephanie Desage, Linda Khouatra, Catherine Battie, Muriel Doret-Dion, Christine Trzeciak, Yesim Dargaud

BLOOD COAGULATION & FIBRINOLYSIS (2020)

Article Hematology

A new paradigm for personalized prophylaxis for patients with severe haemophilia A

Xavier Delavenne, Edouard Ollier, Anne Lienhart, Yesim Dargaud

HAEMOPHILIA (2020)

Article Hematology

Hemostatic effect of tranexamic acid combined with factor VIII concentrate in prophylactic setting in severe hemophilia A: A preclinical study

Maissa Janbain, Nathalie Enjolras, Jean-Claude Bordet, Radu Bolbos, Marie Brevet, Cindy Leissinger, Yesim Dargaud

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

Article Hematology

Hypofibrinolytic state and high thrombin generation may play a major role in SARS-COV2 associated thrombosis

Christophe Nougier, Remi Benoit, Marie Simon, Helene Desmurs-Clavel, Guillaume Marcotte, Laurent Argaud, Jean Stephane David, Aurelie Bonnet, Claude Negrier, Yesim Dargaud

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

Article Hematology

Reversal of rivaroxaban anticoagulant effect by prothrombin complex concentrates: which dose is sufficient to restore normal thrombin generation?

Lorine Giffard-Quillon, Helene Desmurs-Clavel, Claire Grange, Yohann Jourdy, Yesim Dargaud

THROMBOSIS JOURNAL (2020)

Meeting Abstract Cardiac & Cardiovascular Systems

Arterial and Venous Thromboembolism in Covid-19: A Study-level Meta-analysis

Vicky Mai, Kim Boun Tan, Sabine Mainbourg, Arnaud Frigerri, Laurent Bertoletti, Marion Douplat, Yesim Dargaud, Claire Grange, Steeve Provencher, Jean-Christophe Lega

CIRCULATION (2020)

Article Hematology

Personalized treatment for haemophilia

Yesim Dargaud

HEMATOLOGIE (2020)

Meeting Abstract Hematology

Is it dangerous to treat previously untreated patients with severe hemophilia A with recombinant factor VIII concentrates?

Nicolas Drillaud, Anne Lienhart, Antoine Babuty, Yesim Dargaud, Valerie Chamouard, Marc Trossaert, Marc Fouassier, Lucia Rugeri, Marianne Sigaud, Carole Lefranc, Catherine Ternisien, Sandrine Meunier

HAEMOPHILIA (2020)

Meeting Abstract Hematology

MOTIVATE: MODERN TREATMENT OF INHIBITOR-POSITIVE PATIENTS WITH HEMOPHILIA A - AN INTERNATIONAL OBSERVATIONAL STUDY

C. Escuriola-Ettinghausen, R. F. Sidonio, J. Oldenburg, B. Pezeshkpoor, J. Mueller, B. A. Konkle, S. L. Meeks, Y. Dargaud, A. Pavlova, G. Young, J. Snedeker

HAEMATOLOGICA (2019)

Meeting Abstract Hematology

Thrombin generation assay to guide replacement therapy in patients with factor XI deficiency undergoing elective surgery

S. Desage, X. Vanhoye, S. Meunier, L. Rugeri, A. Lienhart, C. Nougier, Y. Dargaud

HAEMOPHILIA (2019)

No Data Available